H1N1 flu vaccine to hit market soon
![swine flu vaccine](/IMG/168/46168/swinefluvaccine.jpg)
Increase in the number of positive swine flu cases, has put a lot of
pressure on the government to look for an early vaccine trials and
making it available in the market. And we are ready. Well, almost!
Indian fast bowler S Sreesanth was tested positive for swine flu,
showing that the flu is still hovering in some parts of the country.
The global outbreak of H1N1/09 virus popularly known as
‘swine flu’, was first detected in April 2009, in
Veracruz, Mexico, with an evidence that there had been an ongoing
epidemic for several months before it was officially recognized. In
India, the first case of the flu was detected in the first week of
August 2009 when a girl from Pune succumbed to the virus. Followed by a
staggering number of deaths caused by swine flu virus, the country came
into the grip of this pandemic outbreak. By September 2009,
India’s position was at its edge. The country had to deal
both with dueling outbreaks of swine flu and related panic.
Recently, around 175 fresh cases have been reported, and the death toll
has touched a record high of 700, and over 21,000 people have been
affected in the country. Maharashtra tops the list in terms of the
casualty figure, the number in this state has jumped to 240. Death toll
in Gujarat so far shows 57 and 94 in Rajasthan. After Maharashtra,
Karnataka with 123 deaths is second in terms of death toll from the
pandemic H1N1 influenza.
Speaking to BioSpectrum, Dr Vishwa Mohan Katoch, director general,
Indian Council of Medical Research (ICMR) says, “We have
always encouraged the Indian companies to take the initiative as an
indigenously developed vaccine may be safe and suitable for the Indian
population. The government is very cautious in its approach and would
not like to take any action in a hurry as the matter is directly linked
to people’s health. Proper trials are a must so that all
the safety issues are addressed before the release of vaccine
in the market. First time in India, all precautions have been taken and
the maximum safety needs have been addressed in this regard.”
Dr Katoch, also the secretary of the Department of Health Research,
Ministry of Health and Family Welfare, says, “Increase in the
number of positive swine flu cases, has put a lot of pressure on the
government to look for an early vaccine trials and making it available
in the market.”
As the origin of the outbreak was traced in Mexico where nearly 200
people died in 1968, the World Health Organization (WHO) made loud
campaigns that resonated at every nook and corner of the globe,
compelling governments to launch surveillance and preventive measures.
And India, which started working on a vaccine from April 2009 soon
after the pandemic spread abroad, is among the first few countries to
get into the fast-track to develop the indigenous swine flu vaccine.
In order to avoid repetition of past experiences which indicated that
during global epidemic, countries where these vaccine manufacturing
units were located would lay the first claim on the products, WHO
selected six companies — Serum Institute of India (SII)
(India), Birmex (Mexico), Bio Farma (Indonesia), Government
Pharmaceutical Organization (Thailand), Vabiotech (Vietnam) and
Butantan (Brazil)— to equip them with the expertise,
technical assistance and production capability to develop and
manufacture any new pandemic influenza vaccine. WHO’s
preparations came handy in the current situation. The seed virus of
H1N1, isolated from the first set of patients in Mexico and California
were quickly sent to the newly identified companies worldwide.
Drug Controller General of India has approved the four stains made
available by WHO. Based on these stains, the H1N1 vaccine is being
developed at Serum Institute, Panacea and Bharat Biotech. Out of the
three, India’s largest biotech company and also one of the
world’s top pediatric vaccine makers, the 42-year-old Serum
Institute is the lead player from the country in the global race to
develop an effective vaccine against the swine flu virus. The
government this time got actively engaged to deal with the situation,
and is learning the ways to deal with such pandemic issue. It is for
the first time that the Indian government and the industry worked in
tandem to tackle the pandemic flu.
Maintaining that the progress in the making of the vaccine is going
head-on, Rajeev Dhere, senior director of SII, says, “The
present status of the vaccine is that animal toxicity studies have been
completed. We will be going for human trials, hopefully this
month.” SII is making two vaccines: Live attenuated vaccine
to be given intra-nasally and an Inactivated vaccine to be
given by injection. The vaccine is ready. Live attenuated vaccine has
been sent to the National Control Laboratory for testing. Likewise,
Bharat Biotech too has submitted the animal trials report to the
regulator and government. “We are waiting for the
government’s nod to undertake human trials,” says
Dr Krishna M Ella, chairman and MD, Bharat Biotech.
According to Dr Katoch, “There is an ethical committee in
every company and the volunteers of 2-200 per group have been used to
check the bridge effect and the adverse effect. Primarily, the health
workers are being targeted for the trials as they are at the higher
risk and later on other segments of population will be
involved.”
“We are highly optimistic about the early success of the
trials. We are hopeful that all the trials would be concluded by the
end of December 2009 and the vaccine would be ready for market entry in
January this year,” he adds.
However, it wasn’t a cakewalk for these companies. Initially,
the major challenges for these companies were import of stain and
reagents at a short notice. But government’s help at every
stage was a sigh-of-relief for these companies, especially in a
situation when the panic button had been pushed too hard. Dr Dhere
adds, “Every day is a challenge but this one was
‘race against time’, for which we required
co-ordination from all agencies both internal and external. It was a
joint effort, and over 10 agencies were roped in for the manufacture of
the vaccine. Besides the organization, we got ample support from the
government, WHO, ICMR, DCGI National Control Laboratory, Kasauli and
National Institute of Virology.”
Nearly 40 to 50 people are involved in the development process of the
vaccine. The budget allocated for the purpose runs in crores. Dr Ella
says, “We have already invested Rs 15 crore in the project.
The total investment is expected to be Rs 70 crore.” However,
SII refused to reveal its investment.
Understanding the severity of the issue, the companies involved left no
stones unturned in providing state-of-the-art facilities for vaccine
research and development. At SII, the biosafety level (BSL) facilities
have been provided for working purpose. The company’s
manufacturing unit for the vaccine spreads over a sprawling area of
over 15,000 sq ft of land.
Despite the complex and time consuming processes, Indian companies went
head on. Bharat Biotech, began by growing seed strains of the
virus. “To make the virus grow in cell-culture is also a
challenge. It was equally important to maintain the highest level
quality control and production capability,” says Dr Ella.
While Dr Dhere opines that putting both scale of abilities and the
R&D division, could handle the process. “And of
course, the support from the senior management committee was fast
tracked,” he adds.
But the steps taken for the manufacture and development of the vaccine
were different. SII went for an egg-based vaccine development, while
Panacea and Bharat Biotech adopted the cell-culture based vaccine. Dr
Dhere says, “Yield of the vaccine is more in the egg-based
than in cellline vaccine. Considering the type of stain that we
received, if we had gone for the cell-line vaccine then it would have
taken a longer time.” However, Bharat Biotech which has the
facility to produce one million doses of vaccine per year, is of the
opinion that egg-based manufacturing process is highly labor intensive,
and during flu pandemic, lack in the supply of eggs may arise. To avoid
such issues, the Hyderabad-based biotech company chose to develop
cell-culture vaccine.
“Cell-culture based vaccines give us the ability to control
all aspects of the manufacturing process from start to finish in a
single facility using close systems without the requirement of manual
handling during the manufacturing process. Cell-culture based vaccines
are not dependent upon any external supplies for the manufacturing
process that could hinder the supply of the vaccine,” says Dr
Ella.
The cell-culture substrates available at Bharat Biotech have been
tested extensively at international laboratories for safety and
quality. It also has extensive expertise in using cell-culture to
manufacture other vaccines such as INDIRAB (rabies vaccine) and is also
developing cell-culture vaccines for rotavirus, Japanese encephalitis
and chikungunya.
Besides these three companies in India, Ahmedabad-based Zydus Cadilla
has come forward and invested in the vaccine development.
“Zydus Cadilla, did not get the seed money from the
government, but they have put their own investment in the vaccine
development. Recently, they got a nod from the DCGI to carry out human
studies of its vaccines. And hopefully, the outcome would be
good,” says Dr Katoch.
Further, he informed that GlaxoSmithKline and Baxter are two companies
among the three international companies with whom the government had
been negotiating on the vaccine trials. “Once the vaccines
are finalized from one of the international companies, then phase IV
trials will be conducted to check the safety and immunogenicity of the
foreign made vaccine on the Indian population.” Dr Katoch
adds, “We are in negotiations on that and will be developing
a fast-track protocol for the same.”
Although the sign of progress in terms of H1N1 vaccine development is
quite satisfactory, but one can’t rule out the re-emergence
of the killer virus and the technological challenges in increasing the
quantity of the H1N1 vaccine once it is approved by the regulators for
large scale use. Fresh positive cases being reported almost every week
and warning bells ringing loud against the impending danger
indicate that the time is running out for India, we need to be
prepared.
Anjana Pradhan in
Bangalore & Rahul Koul in New Delhi